| Ytd | -63.18% | |
| 1y | -88.09% |
| Open | 0.22 | Prev Close | 0.23 | Low | 0.21 | High | 0.26 | Mkt Cap | 9.97M |
| Vol | 14.21M | Avg Vol | 1.90M | EPS | -1.83 | P/E | N/A | Forward P/E | -1.49 |
| Beta | 0.78 | Short Ratio | 1.69 | Inst. Own | 53.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.60 | 200-d Avg | 1.73 | 1yr Est | 13.00 |
VTGN News
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in S
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fased
Vistagen's Phase 3 fasedienol trial missed its main endpoint, but the company found a severe-pat
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%.
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up
PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical tr
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the